Ovarian Cancer Drugs Market To Reach $5.65 Billion By 2030

September 2023 | Report Format: Electronic (PDF)

Ovarian Cancer Drugs Market Growth & Trends

The global ovarian cancer drugs market size is expected to reach USD 5.65 billion by 2030, registering a CAGR of 6.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.

Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.

Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.

key Request a free sample copy or view report summary: Ovarian Cancer Drugs Market Report

Ovarian Cancer Drugs Market Report Highlights

  • Based on treatment, the hospital pharmacy segment held the largest revenue share of 45.37% in 2022. An increasing number of government initiatives and funding for cancer research and treatment are driving drug development and accessibility, ensuring that effective ovarian cancer drugs are available in hospital settings. Based on application, the commercial segment dominated with the largest revenue share of 88.0% in 2022. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth

  • For instance, in 2020, according to the Commonwealth of Australia, the Australian Government allocated USD 16.2 million toward eight research projects dedicated to addressing ovarian cancer. In Australia or globally, ovarian cancer has consistently maintained the lowest survival rate among all female cancers. On average, 43 out of every 100 women diagnosed with ovarian cancer survived five years after their diagnosis.

  • The online pharmacy segment is expected to grow at the fastest CAGR of 8.1% over the forecast period. The convenience of online pharmacies in facilitating the ordering and delivery of ovarian cancer drugs directly to patients' homes, particularly those with health limitations, is a significant driver of the online pharmacy segment in the ovarian cancer drugs treatment market. This accessibility eliminates barriers to obtaining essential medications, enhancing patient adherence to treatment regimens and expanding the market reach for these drugs.

  • For instance, AdooQ BioScience provides a convenient platform for customers to order ovarian cancer drugs, specifically Rucaparib. On the webpage, customers can access detailed information about the drug, including its name, description, dosage forms, and pricing.

  • North America dominated the industry with a market share of 43.47% in 2022 due to various factors, such as the high incidence of ovarian cancer in North America is a key driver of the region's ovarian cancer drugs market as it results in a significant and ongoing demand for effective treatments, fostering pharmaceutical research, and innovation to cater to the needs of the substantial patient population.

  • For instance, according to the American Cancer Society's 2023 estimates for ovarian cancer in the United States, approximately 19,710 women are expected to be newly diagnosed, while approximately 13,270 women are projected to lose their lives to ovarian cancer. ·     

  • Asia Pacific is expected to witness the fastest CAGR of 8.0% over the forecast period due to the increased participation in clinical trials in the region not only provides ovarian cancer patients with access to cutting-edge treatments but also fosters drug development by attracting pharmaceutical companies and researchers, thereby advancing the ovarian cancer drugs market in the region. ·     

  • For instance, according to the Clinical Trials Arena, from 2017 to 2022, Asia Pacific experienced an impressive increase of approximately 10% in clinical trials, surpassing the growth rate observed in other major regions like the U.S. and Europe. This growth in the region significantly outpaced the overall average of 5.3% per year during the same period.

Ovarian Cancer Drugs Market Segmentation

Grand View Research has segmented the global ovarian cancer drugs market on the basis of therapeutic class, treatment, end-use, and region:

Ovarian Cancer Drugs Therapeutic Class Outlook (Revenue, USD Million, 2018 - 2030)

  • PARP Inhibitors

  • Angiogenesis Inhibitors

  • PD-L1 Inhibitors

Ovarian Cancer Drugs End-use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

Ovarian Cancer Drugs Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Chemotherapy

  • Radiation Therapy

  • Hormonal Therapy

  • Targeted Therapy & Others

Ovarian Cancer Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait

List of Key Players in the Ovarian Cancer Drugs Market

  • AbbVie Inc.

  • Pfizer, Inc.

  • AstraZeneca

  • F. Hoffmann-La Roche AG

  • Johnson & Johnson Services, Inc.

  • Boehringer Ingelheim International GmbH

  • Clovis Oncology

  • ImmunoGen, Inc.

  • Vivesto AB

gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.